Skip to main content

Table 1 Descriptive clinicopathological data of participating patients

From: Genetic polymorphisms in key hypoxia-regulated downstream molecules and phenotypic correlation in prostate cancer

 

BPH

OCPCa

EPCa

Age at diagnosis, yrs

67.8 ± 8.4

61.3 ± 6.4

63.3 ± 6.3

PSA at diagnosis, ng/mL

5.5 ± 5.1

6.6 ± 2.4

11.9 ± 5.6

Weight of the prostate, g

94.8 ± 32.1

45.9 ± 14.3

56.6 ± 22.7

Gleason Score

 <7

−

14 (43.8)

0 (0.0)

 ≥7

−

18 (56.3)

19 (100)

 Percentage of tumor a, %

−

15.0 (6.3−20.0)

57.0 (28.8−78.8)

  1. Continuous variables were parametric (Shapiro-Wilk) (data presented as mean ± standard deviation) except for percentage of tumor [data shown as median (interquartile range)]. Categorical variable is depicted as number of observations and respective frequencies. BPH nodular prostate hyperplasia, EPCa extra prostatic cancer, OCPCa organ-confined prostate carcinoma, PSA prostate specific antigen
  2. a on prostatectomy specimens